
Venzide 37.5 Capsule XR
Marketer
Emocare
Salt Composition
Venlafaxine (37.5mg)
Overview Venzide 37.5 Capsule XR
Axilon 37.5mg Extended-Release Capsules treat depression and anxiety. This medication modifies brain chemistry, alleviating anxiety symptoms like agitation, hyperactivity, poor concentration, lethargy, perspiration, tachycardia, and intrusive thoughts. Axilon 37.5mg Extended-Release Capsules should be taken with food, at the same time daily for consistent blood levels. Missed doses should be taken immediately upon recall; do not skip doses, and complete the prescribed course even with symptom improvement. Abrupt cessation is inadvisable, as it may exacerbate symptoms. Common side effects include nausea, emesis, sleep disturbances, appetite reduction, anxiety exacerbation, constipation, hyperhidrosis, and sexual dysfunction. Dizziness and somnolence may occur; avoid activities requiring alertness until the medication's effects are known. These side effects are usually transient and self-limiting. Consult your physician if symptoms persist or are bothersome. Prior to initiating Axilon 37.5mg Extended-Release Capsules, disclose any kidney, heart, or liver conditions, or history of seizures. Report any unusual mood or behavioral shifts, worsening depression, or suicidal ideation to your doctor immediately.
Uses of Venzide 37.5 Capsule XR
Mood disorders encompassing depressive and anxious symptoms
Major Benefits of Venzide 37.5 Capsule XR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and timeframe. Ingest the entire capsule; avoid chewing, crushing, or breaking it. Venzide 37.5mg Extended-Release Capsules should be administered with a meal.
Common Side effects of Venzide 37.5 Capsule XR:
- Nausea
- Vomiting
- Dizziness
- Insomnia (difficulty in sleeping)
- Decreased appetite
- Anxiety
- Constipation
- Increased sweating
- Sexual dysfunction
How to use Venzide 37.5 Capsule XR:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the capsule whole; avoid chewing, crushing, or fracturing it. It is recommended to take Venzide 37.5 mg Extended-Release Capsules with food.
How Venzide 37.5 Capsule XR works:
Extended-release Venzide 37.5mg capsules elevate brain levels of serotonin and noradrenaline, neurotransmitters crucial for emotional equilibrium.
SAFETY ADVICE
AlcoholUNSAFE
Combining Venzide 37.5 Capsule XR and alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
Extended-release Venzide 37.5mg capsules might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Venzide 37.5mg capsules are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant. Close observation of infants for drowsiness and satisfactory weight increase is recommended.
DrivingUNSAFE
Driving ability may be impaired by Venzide 37.5 Capsule XR, due to potential side effects including dizziness, confusion, and visual disturbances like blurred vision.
KidneyCAUTION
Patients with kidney impairment should exercise caution when using Venzide 37.5 XR capsules; dosage modification may be necessary. Physician consultation is advised.
LiverCAUTION
Extended-release Venzide 37.5mg capsules require careful administration for individuals with hepatic impairment. Dosage modification of Venzide 37.5mg extended-release capsules may be necessary. Physician consultation is recommended.
What if you forget to take Venzide 37.5 Capsule XR :
Should you forget to take a Venzide 37.5 Capsule XR, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.
Facts to Know About Venzide 37.5 Capsule XR
| Label | Value |
|---|---|
| Chemical Type | Anisole-based compound |
| Developing Habits | No. |
| Treatment Category | Neuroscience of the Central Nervous System |
| Behavioral Class | SNRIs (serotonin-norepinephrine reuptake inhibitors) |
